GlycoMimetics, Inc. (GLYC)

Oncology Corporate Profile

Stock Performance

6.3600
0.1100

HQ Location

401 Professional Drive #25
Gaithersburg, MD 20879

Company Description

GlycoMimetics is a clinical stage biotechnology company focused on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in which carbohydrate biology (glycobiology) plays a key role. Glycomimetics are molecules that mimic the structure of carbohydrates involved in important biological processes. Using its expertise in carbohydrate chemistry and knowledge of carbohydrate biology, GlycoMimetics is developing a pipeline of glycomimetic drug candidates that inhibit disease-related functions of carbohydrates, such as the roles they play in inflammation, cancer and infection.

Website: http://www.glycomimetics.com

This company does not have any commercial products
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
GMI-1271E-selectin antagonistAcute Myelogenous Leukemia (AML)I

View additional information on product candidates here »

Source


http://www.glycomimetics.com

Recent News Headlines

GlycoMimetics Appoints Scott Koenig of MacroGenics to Board of Directors

3/13/2017 01:03 pm

[Business Wire] - GlycoMimetics, Inc. announced today the appointment of Scott Koenig, M.D., Ph.D., to its Board of Directors. Dr. Koenig is President and Chief Executive Officer and a member of the Board of Directors of MacroGenics , a company specializing in antibody-based therapies for cancers and other diseases.

GlycoMimetics Completes Enrollment of Newly Diagnosed AML Patient Cohort in Phase 2 Clinical Trial of GMI-1271

3/7/2017 02:00 pm

[Business Wire] - GlycoMimetics, Inc. today announced that the first of two patient cohorts in its Phase 2 acute myeloid leukemia trial of GMI-1271 has completed enrollment. This cohort is comprised of 25 patients 60 years of age or older with newly diagnosed AML.

GlycoMimetics to Present New Preclinical Data in Multiple Myeloma at AACR Annual Meeting 2017

3/2/2017 01:05 am

[Business Wire] - GlycoMimetics, Inc. today announced that pre-clinical research demonstrating the potential of two of its drug candidates, GMI-1271 and GMI-1359, against multiple myeloma will be shared via an oral presentation at the American Association for Cancer Research Annual Meeting 2017 in Washington, DC.

GlycoMimetics Reports Fourth Quarter and Year-End 2016 Results

3/1/2017 02:03 pm

[Business Wire] - GlycoMimetics, Inc. today reported progress on its clinical development programs and its financial results for the fourth quarter and year ended December 31, 2016.

GlycoMimetics to Present at Cowen 37th Annual Health Care Conference

2/28/2017 09:00 pm

[Business Wire] - GlycoMimetics, Inc. today announced that Chief Executive Officer Rachel King will provide a company overview at the Cowen 37th Annual Health Care Conference in Boston, on Tuesday, March 7, 2017, at 10:40 a.m.

GlycoMimetics' GMI-1271 Continues to Yield High Remission Rates, Favorable Tolerability in Two Phase 2 Arms of Ongoing Phase 1/2 Clinical Trial for AML

12/5/2016 03:00 pm

[Business Wire] - GlycoMimetics, Inc. today announced that results of its Phase 1/2 clinical trial on its lead drug candidate GMI-1271 continued to show high rates of remission and favorable tolerability among study participants with acute myeloid leukemia .

GlycoMimetics to Present at Upcoming Healthcare Investor Conferences

11/10/2016 02:01 pm

[at noodls] - ROCKVILLE, Md.--(BUSINESS WIRE)-- GlycoMimetics, Inc. (NASDAQ: GLYC) today announced that Chief Executive Officer Rachel King will provide a company overview at two healthcare investor conferences next ...

GlycoMimetics to Present at Upcoming Healthcare Investor Conferences

11/10/2016 02:00 pm

[Business Wire] - GlycoMimetics, Inc. today announced that Chief Executive Officer Rachel King will provide a company overview at two healthcare investor conferences next week, as fol

GlycoMimetics to Present Preclinical Cancer Results at Society for Immunotherapy of Cancer Meeting

11/8/2016 02:00 pm

[Business Wire] - GlycoMimetics, Inc. today announced that data showing enhanced effectiveness of an antibody antagonist to a key cancer regulatory ligand, PD-L1, in combination with its drug candidate GMI-1359 will be presented at the Society for Immunotherapy of Cancer Annual Meeting & Associated Programs.

GlycoMimetics Reports Third Quarter 2016 Results and Progress in Clinical Development

11/4/2016 02:00 pm

[at noodls] - ROCKVILLE, Md.--(BUSINESS WIRE)-- GlycoMimetics, Inc. (NASDAQ: GLYC) today reported progress on its clinical development programs and its financial results for the quarter ended September 30, 2016. ... ...